Tipelukast

Last updated
Tipelukast
Tipelukast.svg
Names
IUPAC name
4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenyl)sulfanylpropoxy]-2-propylphenoxy]butanoic acid
Other names
KCA 757; MN-001
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
DrugBank
KEGG
PubChem CID
UNII
  • InChI=1S/C29H38O7S/c1-5-9-23-25(14-12-22(20(4)31)29(23)36-16-7-11-27(32)33)35-17-8-18-37-26-15-13-21(19(3)30)28(34)24(26)10-6-2/h12-15,34H,5-11,16-18H2,1-4H3,(H,32,33)
    Key: KPWYNAGOBXLMSE-UHFFFAOYSA-N
  • CCCC1=C(C=CC(=C1OCCCC(=O)O)C(=O)C)OCCCSC2=C(C(=C(C=C2)C(=O)C)O)CCC
Properties
C29H38O7S
Molar mass 530.68 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Tipelukast (KCA 757 or MN-001) is a sulfidopeptide leukotriene receptor antagonist with suspected anti-inflammatory properties. It is developed by MediciNova. [1] [2] [3] [4]

References

  1. ↑ "MN-001 - MediciNova, Inc". medicinova.com. Retrieved 3 December 2023.
  2. ↑ Rajasekaran, Mahadevan; Locke, Kenneth W.; Parsons, C. Lowell (August 2006). "MN-001, a novel oral anti-inflammatory agent, suppresses bladder hyperactivity in a rat model". BJU International. 98 (2): 430–434. doi:10.1111/j.1464-410X.2006.06274.x. PMID   16879690. S2CID   44269457.
  3. ↑ Matsuda, Kazuko; Iwaki, Yuichi (December 2014). "MN-001 (tipelukast), a novel, orally bioavailable drug, reduces fibrosis and inflammation and down-regulates TIMP-1, collagen Type 1 and LOXL2 mRNA overexpression in an advanced NASH (nonalcoholic steatohepatitis) model: LB-28". Hepatology. 60 (6): 1283A. ISSN   0270-9139.
  4. ↑ Bascom, R.; Hitz, K.; Dimmock, A.E.F.; Makhay, M.; Dojillo, J.; Matsuda, K. (May 2020). "Description of Protocol to Evaluate MN-001'S (tipelukast) Efficacy, Safety and Tolerability in Subjects with Idiopathic Pulmonary Fibrosis". A37. Ild Therapy I. pp. A1493. doi:10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A1493. S2CID   225921518.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.